Biomea Fusion, INC

Biomea Fusion, Inc. announced the results of its Annual Meeting of Stockholders, including the election of two directors and the ratification of its independent auditor.

Biomea Fusion announced its first quarter 2026 financial results, highlighting progress in its icovamenib and BMF-650 clinical trials for diabetes and obesity, with a projected cash runway into Q1 2027.

Biomea Fusion announced positive 52-week topline results from its Phase 2 COVALENT-112 study of icovamenib in Type 1 Diabetes patients, showing significant C-peptide increase and durability.

Biomea Fusion, Inc. announced its full year 2025 financial results, highlighting significant progress in its diabetes and obesity clinical programs and a reduced net loss.

Biomea Fusion, Inc. updated its corporate presentation, highlighting progress in its diabetes and obesity programs, icovamenib and BMF-650, with key clinical data readouts anticipated in 2026 and funding secured into Q1 2027.

Biomea Fusion presented positive 52-week data for its diabetes drug Icovamenib and preclinical results for its obesity candidate BMF-650 at the J.P. Morgan Healthcare Conference.

Biomea Fusion, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $12.4 million and a cash balance of $45.1 million, while strategically shifting focus to metabolic diseases.

Biomea Fusion reported a reduced net loss but faces substantial doubt about its ability to continue as a going concern, necessitating further capital raises.

Biomea Fusion, a clinical-stage biotech, reported significant losses and a going concern warning, despite recent capital raises and ongoing clinical trials for diabetes and obesity therapies.

Biomea Fusion reports a net loss for Q1 2025 and expresses concerns about its ability to fund operations beyond Q4 2025 without additional financing.

Biomea Fusion's Q3 2024 report details financial results, including a net loss of $109.1 million for the nine months ended September 30, 2024, and provides updates on their clinical programs, including the lifting of a clinical hold on icovamenib trials.

Biomea Fusion's Q2 2024 report reveals increased R&D spending and a clinical hold on BMF-219 diabetes trials, alongside ongoing oncology program advancements.

Biomea Fusion, a clinical-stage biopharmaceutical company, reported a reduced net loss in 2025 but faces substantial doubt about its ability to continue as a going concern, while strategically focusing on diabetes and obesity treatments.

Biomea Fusion's 10-K filing reveals a strategic shift towards diabetes and obesity treatments, alongside a leadership transition and updates on clinical programs.

Biomea Fusion's 10-K filing highlights its clinical-stage progress in developing covalent small molecule drugs for genetically defined cancers and metabolic diseases, particularly diabetes.

Director Julianne Averill was granted 173,711 stock options with an exercise price of $1.15 as part of her compensation package.

Biomea Fusion's President and COO, Rainer M. Erdtmann, acquired 30,000 shares of common stock, signaling strong insider confidence.

Biomea Fusion's Interim CEO, Michael J.M. Hitchcock, acquired 100,000 shares of common stock at a weighted average price of $0.9918 per share.

Biomea Fusion's President and COO, Rainer M. Erdtmann, increased his direct and indirect holdings of common stock through recent purchases.

Biomea Fusion's Interim CEO and Director, Michael J.M. Hitchcock, was granted 916,434 stock options with an exercise price of $1.53, vesting quarterly over four years.

Biomea Fusion's President and COO, Rainer M. Erdtmann, reported gifting shares of common stock to family members and updating his beneficial ownership.

Biomea Fusion, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, to elect directors and ratify auditor appointment.

Biomea Fusion is holding its 2025 Annual Meeting of Stockholders on June 11, 2025, to elect directors, ratify the appointment of Deloitte & Touche LLP, and approve an amendment to the company's certificate of incorporation.

Biomea Fusion's 2024 Annual Meeting of Stockholders will address the election of two Class III directors and the ratification of Deloitte & Touche LLP as the independent auditor.

Cormorant Asset Management and its affiliated funds have significantly reduced their beneficial ownership in Biomea Fusion, Inc., falling below the 5% threshold.

Cormorant Asset Management and affiliates updated their beneficial ownership in Biomea Fusion, Inc. to 5.31% following a recent public offering.

Cormorant Asset Management, LP and its managing member Bihua Chen have updated their beneficial ownership in Biomea Fusion, Inc. to an aggregate of 6.46% following the company's recent public offering.

CVI Investments, Inc. and Heights Capital Management, Inc. disclose a continued 9.9% beneficial ownership in Biomea Fusion, Inc. via warrants.

Blue Owl Capital Holdings LP has reported a 5.92% beneficial ownership stake in Biomea Fusion, Inc., primarily through warrants.

Rainer M. Erdtmann updated his beneficial ownership in Biomea Fusion, Inc., now holding 3.9% of common stock after resigning from Point Sur Investors.

Janus Henderson Group plc has reported a beneficial ownership of 8.2% in Biomea Fusion, Inc., holding 3,750,000 shares of common stock.

Blue Owl Capital Holdings LP has reported a 3.42% beneficial ownership stake in Biomea Fusion, Inc., primarily through warrants.

CVI Investments and Heights Capital Management have reported a 9.9% beneficial ownership stake in Biomea Fusion, Inc., totaling 6,445,151 shares.